Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis

Clinical trial condition

Hepatitis

Explore clinical trials studying Hepatitis. Study availability and eligibility vary by location and protocol.

2,967 public trials 189 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis trial results

Completed

Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

NCT01112033

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague Prague, Czechia

View Trial Details

Completed

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."

NCT02196064

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +20 more
Locations: Fundación Pública Andaluza Progreso y Salud Seville, Sevilla, Spain

View Trial Details

Completed

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.57.0001 Boehringer Ingelheim Investigational Site Atlanta, Georgia, United States

1220.57.0002 Boehringer Ingelheim Investigational Site Overland Park, Kansas, United States

1220.57.0003 Boehringer Ingelheim Investigational Site Salt Lake City, Utah, United States

View Trial Details

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

NCT01579474

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.54.08104 Boehringer Ingelheim Investigational Site Chuo-ku, Chiba, Japan

1220.54.08118 Boehringer Ingelheim Investigational Site Chuo-ku, Kobe, Hyogo, Japan

1220.54.08108 Boehringer Ingelheim Investigational Site Fukui, Fukui, Japan

1220.54.08110 Boehringer Ingelheim Investigational Site Gifu, Gifu, Japan

View all 24 locations

View Trial Details

Completed

Drug-drug Interaction of BI 201335 and Microgynon

NCT01570244

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: 1220.56.1 Boehringer Ingelheim Investigational Site Biberach, Germany

View Trial Details

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

NCT01704846

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.53.08101 Boehringer Ingelheim Investigational Site Sumida-ku,Tokyo, Japan

View Trial Details

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

NCT01580306

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.58.1 Boehringer Ingelheim Investigational Site Kiel, Germany

View Trial Details

Completed

Behavioral Science Aspects of Rapid Test Acceptance

NCT01317784

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Blood-Borne Infections, +22 more
Locations: Center for Behavioral Research and Services Long Beach, California, United States

View Trial Details

Completed

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

NCT00728494

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Not specified

View Trial Details

Completed

Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

NCT02269059

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details